Key Highlights

  • ROIV shares rose 8.63% pre-market to $37.94 from a $34.92 prior close.
  • Brepocitinib met the primary and all key secondary endpoints in two Phase 3 uveitis trials.
  • Median time to treatment failure exceeded 48 weeks versus about 12 weeks for placebo.
  • Priovant plans to file a supplemental NDA in the first half of 2027.

Phase 3 Uveitis Success Drives the Move

Roivant (NASDAQ:ROIV) shares rose 8.63% pre-market today to $37.94, up $3.02 from the prior close of $34.92. The move follows news from Roivant and its subsidiary Priovant that brepocitinib 45 mg once daily showed statistically significant benefit over placebo on the primary endpoint and all key secondary endpoints. The results come from CLARITY-1 and CLARITY-2, the two identical Phase 3 trials in non-infectious uveitis.

The two trials enrolled 371 patients. Median time to treatment failure was more than 48 weeks on brepocitinib versus about 12 weeks on placebo, and no new safety signals were reported. The stock closed the prior session up 0.63%, after trading between $34.38 and $35.52.

Second Indication Extends the Franchise

Priovant plans to file a supplemental new drug application in the first half of 2027. Brepocitinib was recently approved as LISRAYA for adults with dermatomyositis, so the uveitis data extend the drug into a second indication. The JAK1 and TYK2 inhibitor is also in late-stage development for cutaneous sarcoidosis and lichen planopilaris.

The health sector hit record highs on Tuesday, with the XLV ETF up 2.2%, so Roivant is moving higher against a strong sector backdrop.

Pipeline and Valuation Snapshot

Roivant is a commercial-stage biopharmaceutical company that builds nimble subsidiaries, called "Vants", to develop and commercialize medicines. Beyond brepocitinib, its pipeline includes IMVT-1402, a fully human antibody targeting FcRn for IgG-mediated autoimmune diseases, and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.

The company reports a loss of $1.05 per share. The 52-week range runs from $17.64 to $42.50, so the pre-market price sits nearer the high end. Volume reached 3.62 million shares in the last session.

Next Up: November 9 Report

Roivant will report results for the quarter ended September 30, 2026, and give a business update on a live call at 8:00 a.m. ET on Monday, November 9. An investor day follows on Wednesday, December 9.